Original research article

Validity of hemoglobin A1c for diagnosing diabetes among people with and without HIV in Uganda

James Muchira[1] (iD), **Eileen Stuart-Shor[2], Jen Manne-Goehler[3,4], Janet Lo[4,5], Alexander C Tsai[4,5,6], Bernard Kakukire[6], Samson Okello[3,6] and Mark J Siedner[4,5,6]**

Abstract

Sub-Saharan Africa (SSA) is facing a growing co-epidemic of chronic HIV infection and diabetes. Hemoglobin A1c (A1c) may underestimate glycemia among people living with HIV (PLWH). We estimated the validity of A1c to diagnose diabetes among PLWH and HIV-uninfected persons in rural Uganda. Data were derived from a cohort of PLWH and age- and gender-matched HIV-uninfected comparators. We compared A1c to fasting blood glucose (FBG) using Pearson correlations, regression models, and estimated the sensitivity and specificity of A1c for detecting diabetes with FBG ≥ 126 mg/dL as reference standard. Approximately half (48%) of the 212 participants were female, mean age of 51.7 years (SD = 7.0) at enrollment. All PLWH (n = 118) were on antiretroviral therapy for a median of 7.5 years with mean CD4 cell count of 442 cells/μL. Mean FBG (89.7 mg/dL) and A1c (5.6%) were not different between PLWH and HIV-uninfected ($P > 0.50$) groups, but the HIV-uninfected group had a higher prevalence of A1c $>5.7\%$ (33% vs. 20%, $P = 0.024$). We found a relatively strong correlation between A1c and FBG (r = 0.67). An A1c $\geq 6.5\%$ had a poor sensitivity (46%, 95% CI 26–67%) but high specificity (98%, 95% CI 96–99%) for detecting diabetes. More work is needed to define an optimal A1c for screening diabetes in SSA.

Introduction

By 2040, one in ten adults (642 million) are predicted to have diabetes, with large increases in disease burden expected in countries transitioning from low- to middle-income status.[1] Africa is home to populations with the highest rates of undiagnosed diabetes and many regions are grappling with concurrent infectious and non-communicable disease epidemics.[1,2] For example, the sub-Saharan Africa (SSA) region accounts for nearly 67% of people living with HIV (PLWH) globally[3]; and although treatment scale-up has been successful, the prevalence of diabetes mellitus (DM), cardiovascular disease, and other metabolic disorders are elevated in PLWH.[4,5]

Several factors have been implicated as drivers for the increased risk of diabetes among PLWH, including the increasing lifespan of those infected.[4] Yet, data from the 2009–10 Medical Monitoring Project

(n = 8610), a nationally representative surveillance study of HIV-infected adults in the United States and National Health and Nutrition Survey (n = 5604 general population adults), a nationally representative surveillance study of adults in the general population in the United States, indicate that PLWH had higher

[1]University of Massachusetts Boston, College of Nursing and Health Sciences, Boston, MA, USA
[2]Beth Israel Deaconess Medical Center, Boston, MA, USA
[3]Harvard T.H. Chan School of Public Health, Boston, MA, USA
[4]Massachusetts General Hospital, Boston, MA, USA
[5]Harvard Medical School, Boston, MA, USA
[6]Mbarara University of Science and Technology, Mbarara, Uganda

Corresponding author:
James Muchira, University of Massachusetts Boston, Boston, MA, USA.
Email: James.Muchira@umb.edu

unadjusted prevalence of diabetes (10.3%) compared with the general population (8.3%), with that difference doubling after adjusting for covariates.[6–8] Evidence from Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort and other studies has implicated the use of protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine, which are still widely used in SSA, as contributors to increased diabetes risk.[9,10]

The American Diabetes Association (ADA) now recommends A1c as a screening test for diabetes, in addition to fasting blood glucose (FBG) or Oral Glucose Tolerance Test (OGTT).[11] In 2011, the World Health Organization (WHO) also began recommending A1c as a test for the diagnosis of diabetes.[12] However, there are concerns that A1c underestimates or overestimates glycemia in different ethnic or racial groups with different A1c-genetic variants.[13] Further, A1c can be affected by several factors such as age, shortened red blood cell lifespan, cirrhosis, renal failure and hemolysis, all of which have been associated with HIV infection.[14] Other factors associated with low sensitivity of A1c among PLWH include use of NRTI-based therapy, macrocytosis and/or abacavir use.[15]

In contrast, FBG has been used as a primary test for DM in many low resource settings, owing to its ease of use and low cost. A strong linear relationship between A1c and FBG has been demonstrated in multiple ethnic groups and geographic regions outside of SSA.[16–18] However, some studies have also reported that A1c underestimates blood glucose among PLWH.[15,19] Yet, there are few studies from SSA on the accuracy of using A1c compared with FBG in the general population or among PLWH.[15] This gap in the literature persists despite the high prevalence of HIV in the SSA region and points to a need for targeted research to identify optimal methods for screening for diabetes.[3] We aimed to estimate the relationship and diagnostic accuracy of A1c compared to FBG in a cohort of PLWH on ART and community based, HIV-uninfected comparators. Our overarching aim was to assess the utility of A1c testing in this population as it becomes increasingly available in the region.

Methods

Study population

Data for this analysis were collected as part of the Ugandan Non-Communicable Diseases and Aging Cohort (UGANDAC) Study (NCT02445079), a cohort of PLWH and age and gender-matched HIV-uninfected persons in rural Uganda.[20,21] Study participants were comprised of (1) PLWH aged 40 years and older, in ambulatory care at the HIV Clinic at Mbarara

Regional Referral Hospital, and on ART for a minimum of three years and (2) HIV-uninfected persons recruited from the catchment area of the hospital, who were age- (by quartile) and gender-matched to PLWH.[22] We first enrolled PLWH who met the above inclusion criteria and who were actively in care at the Mbarara Regional Referral Hospital Immune Suppression Syndrome. We then used the population census of Nyakabare Parish, which is a cluster of eight villages approximately 20 km from the clinic, to identify HIV-uninfected comparators. We randomly selected a sample of individuals who were age- and gender-matched (by quartile of PLWH). All HIV-uninfected individuals underwent confirmatory HIV testing on the day of each study visit.

Variables

Participants completed annual visits to collect data on sociodemographic, anthropometric measurements, blood pressure, smoking history using the WHO Tobacco questionnaire,[20] diet, physical activity, body mass index (BMI), and self-reported history and treatment for diabetes and hypertension. Blood was collected for A1c testing using Siemens Vantage A1c testing kits (Siemens Medical Solutions USA, Malvern, PA). A1c testing was done at the time of blood collection using the point-of-care Siemens assay. Serum was stored at −80°C for up to one year before shipment to the United States for serologic testing of glucose and other metabolic parameters. For PLWH, CD4 T-cell counts and HIV-1 RNA viral load were abstracted from medical records. For FBG, whole blood was collected into serum separator tubes and centrifuged and stored at −80°C until testing. Cryopreserved serum samples were tested at LabCorp clinical laboratories for comprehensive metabolic panel (LabCorp, Burlington, NC, USA). Participants were requested to fast from midnight on the days of their procedures, and fasting status is recorded on the date of each visit. All study questionnaires, specimen collection, and A1c testing was performed by study nurses.

Statistical analysis

We included data from all study visits with paired A1c and FBG. We first summarized the cohort and assessed for differences in sociodemographic and clinical characteristics by HIV serostatus. We used Pearson correlation to determine the relationship between A1c and FBG both for the total cohort and by HIV serostatus. We then fit univariable and multivariable linear regression models with robust standard errors to account for repeated measure clustering, with FBG as the dependent variable, and A1c as the primary independent

variable, with and without A1c*HIV serostatus product terms to assess for a modification of the relationship between A1c and FBG by HIV serostatus. We used forward stepwise regression with an alpha threshold of 0.05 to select variables that may influence the relationship between A1c and FBG among PLWH. Such variables included age, gender, BMI or waist circumference, hemoglobin level, MCV, albumin, asset ownership index, and C-reactive protein. Finally, we estimated the sensitivity and specificity of A1c to detect diabetes using ADA thresholds of ≥6.5% for A1c and FBG ≥126 mg/dL as indicative of diabetes[23] and fit a receiver operating characteristic curve (ROC) and calculated the area under ROC (AUC) to determine the optimal threshold of A1c to detect FBG ≥126 mg/dL. For prediabetes, we estimated the sensitivity and specificity of A1c cut off ≥5.7% and FBG ≥100 mg/dL. We used the rocreg command in Stata to account for clustering and used bootstrapping with 1000 repetitions to estimate the standard errors and confidence intervals for the AUC estimations. Statistical analysis was done using Stata version 14 (StataCorp, College Station, TX).

Ethical considerations

Study procedures were approved by institutional review committees at Mbarara University of Science in Uganda and Technology and Partners Healthcare in the United States. Written informed consent was provided by all study participants.

Results

The study enrolled a total of 309 participants, of which 212 (HIV-positive n = 118; HIV-uninfected n = 94) had both FBG and A1c measured simultaneously at least once during observation and were therefore included in this analysis. The remaining participants were excluded due to absence of a visit with FBG and A1c during the study. Participants with missing A1c and FBG values were slightly older (53.6 vs. 52.6, *P* = 0.03); however, no statistically significant differences were found in gender or BMI among those with missing and non-missing A1c and FBG measurements (Supplemental Table 1). Included participants had a mean age of 51.7 years (SD = 7.0) at enrollment, and approximately half (48%) were female (Table 1). Few individuals reported a history of diabetes (n = 12 [5.8%]) or current therapy for diabetes (n = 5 [2.3%]). At enrollment, PLWH (n = 118) were on ART for a median of 7.5 years and the mean CD4 cell count was 442 cells/µL (SD = 179). The prevalence of elevated blood sugar was 6.1% determined by the A1c threshold ≥6.5% and 6.2% determined by the FBG threshold ≥126 mg/dL. PLWH and HIV-uninfected individuals had comparable mean FBG (88.5 vs. 91.2, *P* = 0.55) and comparable

Table 1. Cohort characteristics.

| Characteristic (n%)	Total cohort (n = 212)	HIV-negative (n = 94)	HIV-positive (n = 118)	*P* value
Age (mean/SD)	51.7 (7)	52.2 (6.9)	51.3 (7.1)	0.324
Female	102 (48.1)	45 (47.8)	57 (48.3)	0.95
BMI (mean/SD)	22.7 (4.2)	22.4 (4.5)	22.8 (3.9)	0.431
<18.5	21 (9.9)	14 (14.8)	7 (6.0)	0.099
18.5–24.9	142 (67.0)	62 (66.0)	80 (67.8)	
25.0–29.9	34 (16.0)	11 (11.7)	23 (19.5)	
≥30	15 (7.1)	7 (7.5)	8 (6.8)	
FBG (mean/SD)	89.7 (33.2)	91.2 (34.2)	88.5 (32.5)	0.554
<100 mg/dL	180 (84.9)	77 (81.9)	103 (87.3)	0.553
100–125 mg/dL	19 (9.0)	10 (10.6)	9 (7.6)	
≥126 mg/dL	13 (6.2)	7 (7.45)	6 (5.1)	
A1c	5.6 (1.1)	5.6 (0.96)	5.5 (1.2)	0.687
<5.7%	156 (73.6)	62 (66.0)	94 (79.7)	0.024*
5.7–6.4%	43 (20.3)	27 (28.7)	16 (13.6)	
≥6.5%	13 (6.1)	5 (5.3)	8 (6.8)	
ART therapy				
AZT/3TC/NVP			100 (64.5)	
AZT/3TC/EFV			41 (26.5)	
TDF/3TC/LPV/R			10 (6.5)	
Other			4 (2.5)	
CD4 cell count (median/IQR)			485 (837)	
Nadir CD4 (median/IQR)			131 (432)	

*Statistically significant at 0.05 level.

Figure 1. Scatter plot and predictive regression line demonstrating relationship between A1c and FBG by HIV serostatus.

mean A1c (5.5% vs. 5.6%, $P = 0.69$). However, HIV-uninfected individuals had a higher prevalence of elevated of FBG ≥ 100 mg/dL (18.1% vs. 12.7%, $P = 0.56$) and A1c $>5.7\%$ (33% vs. 20%, $P = 0.02$), despite having a lower prevalence of being overweight (18.9% vs. 26.3%, $P = 0.10$). At enrollment, all PLWH (n = 118) were on ART, the majority of whom (91%) were on nevirapine or efavirenz.

The overall correlation between A1c and FBG was high (r = 0.67, $P < 0.001$) and was similar between PLWH and HIV-uninfected individuals (r = 0.69 vs. r = 0.66, $P = 0.70$). In regression analyses, we estimated a linear relationship between A1c and FBG (see Figure 1): the estimated mean increase in FBG for each 1 unit in A1c was 18 mg/dL (95% CI 10.7–25.0) for the entire cohort, 16 mg/dL (95% CI 9.2–23.2) among PLWH, and 23 mg/dL (95% CI 9. 3–37.2) among HIV-uninfected individuals (P value for interaction =0.349). No statistically significant differences were noted comparing PLWH and HIV-uninfected individuals on A1c and FBG after adjusting for age, gender, and BMI. We estimated sensitivity and specificity for range of A1c cutoff points (see Supplemental Table 2). To detect an elevated FGG for the total cohort at a threshold of ≥ 126 mg/dL, A1c had an AUC of 0.80 (95% CI 0.69–0.92), sensitivity of 46% (95% CI 26–67%) and specificity of 98% (95% CI 96–99%) (Figure 2) at the $\geq 6.5\%$ cutoff. Given the cohort prevalence of diabetes at 6%, A1c had a corresponding positive predictive value of 55% (95% CI 32–77%) and negative predictive value of 97% (95% CI 95–98%).


Area under ROC= 0.80   Sensitivity=46% Specificity=98%

Figure 2. Area under receiver operating curve for A1c predicting FBG values for both cohorts.

At an FGG threshold of ≥ 126 mg/dL, A1c performed better among PLWH (75% sensitivity, 95%CI 43–95%; 99% specificity, 95% CI 96–100%, AUC 0.97, 95% CI 0.93–1.00) compared with HIV-uninfected persons (17% sensitivity, 95% CI 2–48%; 97% specificity, 95%CI 93–99%, AUC 0.58, 95% CI 0.38–0.79). We observed a low prevalence of elevated A1c in subgroups, resulting in large confidence intervals for estimates of sensitivity. At the cutoff of $\geq 5.7\%$, A1c had a sensitivity for detecting FBG ≥ 100 mg/dL of 43% (95% CI 32–55%) and a specificity of 88% (95% CI 85–91%).

Discussion

In this mixed cohort of community dwelling PLWH on ART and HIV-uninfected comparators, we found a strong correlation between A1c and FBG. However, an A1c threshold of ≥6.5% had relatively low sensitivity but a high specificity using a criterion FBG of ≥126 mg/dL. We found no evidence of decreased sensitivity of A1c among PLWH versus HIV-uninfected individuals. Our results suggest that A1c may be an acceptable screening test for diabetes in rural SSA settings, but also a that there is a need to further evaluate the most appropriate threshold for diagnosis, and the possible role for repeated screening to augment sensitivity.

Contrary to our hypothesis, PLWH had similar correlations between A1c and FBG compared to HIV-uninfected persons. Correlations between A1c and FBG were strong overall in this cohort, which is in keeping with prior work across different ethnic groups and geographic regions in North America, South America, Europe, and Asia that have demonstrated a predictably linear relationship between A1c and FBG levels across a FBG range of 100.8–162 mg/dL.[16,18] For instance, a meta-analysis of 14 studies reported a pooled correlation of r = 0.61 (95% CI; 0.48–0.72),[17] remarkably similar to our finding (r = 0.67), and adds support for the use of A1c in principle as a screening test in SSA.

However, we identified a low sensitivity for A1c threshold of ≥6.5% in our study as well, raising questions about the optimal A1c threshold for diabetes screening in rural SSA.[13,24] Data elsewhere have demonstrated a lower A1c threshold may increase overall sensitivity of A1c to screen for diabetes. For example, a large study in the United States suggested an A1c of ≥6.0% was the optimal screening threshold to correspond to an FBG ≥ 126 mg/dL, with a sensitivity of 69.8% and specificity of 91.9%.[25] Using that same A1c threshold of ≥6.0%, we found similar sensitivity of 63% and specificity of 91% in our cohort.

In contrast, the WHO recommends using A1c threshold of 6.5% to diagnose diabetes,[11] noting insufficient evidence to make recommendations at levels below that. The low sensitivity but high specificity of a single A1c to diagnose diabetes in our study supports that recommendation, as do other studies in the field both in the general population and among PLWH. For example, the National Health and Nutrition Examination Survey reported a sensitivity of only 43% for an A1c ≥6.5% to detect elevated FBG at ≥126 mg/dL.[25] Others have reported that women with HIV and diabetes in the US had lower A1c compared with HIV-uninfected comparators with the same FBG values, and that this difference was attenuated after controlling for mean corpuscular volume (MCV) among PLWH.[26] In the Multicenter AIDS Cohort Study, A1c was an average of 0.21% lower among men with HIV compared with HIV-uninfected men at FBG of 125 mg/dL.[19]

In summary, findings from our study suggest that A1c correlates well with FBG but the diagnostic threshold of A1c might need to be altered in SSA to improve sensitivity for diagnosing diabetes. Additional considerations about A1c as a primary screening assay remain, including issues related to its reliance on red cell indices in malaria-endemic regions, and comparative costs versus fasting glucose and oral glucose tolerance tests. Future work should explore these issues with longitudinal observation of individuals, inclusion of malaria and red cell index tests, and repeated measures of glucose testing to better clarify the optimal diagnostic approach to using A1c in this setting.

This study had a number of important limitations. We could not compare A1c to average 2- to 3-month glucose since our data consisted of single fasting glucose measures at annual study visits. Similarly, we were not able to assess the contribution of MCV, hemoglobin, hemoglobinopathies or malaria co-infections to A1c-FBG relationships in the cohort because the measures were not taken among most participants. In addition, we did not have OGTT measures. It is known that A1c and FBG may have limitations of moderate sensitivity compared to OGTT which is known at times to have higher sensitivity. Comparing the accuracy of A1c, FBG and OGTT would be necessary to determine which test has highest diagnostic accuracy. We observed a relatively small sample size of individuals with high FBG, and therefore were underpowered to make strong conclusions about the sensitivity of A1c in sub-groups. We also acknowledge that clustered data can affect interpretation of our correlation coefficients, but this would only impact interpretation if individual-level factors contribute meaningfully to diagnostic validity of hemoglobin A1c in comparison to fasting glucose. Finally, our results should be considered within the context of our study population. For example, our participants were characterized by a rural population, and certain characteristics, such as mean BMI were relatively low in this cohort.

In conclusion, we found a strong correlation between A1c and FBG among individuals in Uganda and no evidence of a difference in this relationship by HIV serostatus. However, an A1c ≥6.5% had a poor sensitivity (46%) but high specificity (98%) to detect elevated FBG in this population. Further studies are needed to validate the optimal strategy of diabetes screening and monitoring in SSA.

Declaration of conflicting interests

Funding

ORCID iD

James Muchira https://orcid.org/0000-0003-4786-5725

References

1. International Diabetes Federation. IDF diabetes atlas. 7th ed., www.diabetesatlas.org/ (2017, accessed 23 April 2017).
2. Institute for Health Metrics and Evaluation. The global burden of disease: generating evidence, guiding policy – Sub-Saharan Africa Regional Edition, www.healthdata.org/policy-report/global-burden-disease-generating-evidence-guiding-policy-%E2%80%93-sub-saharan-africa-regional (2018, accessed 23 January 2018).
3. World Health Organization. HIV/AIDS, www.afro.who.int/health-topics/hivaids (2017, accessed 23 January 2018).
4. UNAIDS. UNAIDS. Chronic care of HIV and non-communicable diseases: How to leverage the HIV experience, http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110526_JC2145_Chronic_care_of_HIV.pdf (2011, accessed 23 January 2018).
5. NCD Risk Factor Collaboration (NCD-RisC) – Africa Working Group. Trends in obesity and diabetes across Africa from 1980 to 2014: an analysis of pooled population-based studies. *Int J Epidemiol* 2017;46:1421–1432.
6. Hernandez-Romieu AC, Garg S, Rosenberg ES, et al. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. *BMJ Open Diab Res Care* 2017; 5: e000304.
7. Frankel MR, McNaghten A, Shapiro MF, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. *Open AIDS J* 2012; 6: 67–76.
8. Centers for Disease Prevention and Control. About the National Health and Nutrition Examination Survey, www.cdc.gov/nchs/nhanes/about_nhanes.htm (2017, accessed 22 November 2018).
9. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008; 31: 1224–1229.
10. Kalra S, Kalra B, Agrawal N, et al. Understanding diabetes in patients with HIV/AIDS. *Diabetol Metab Syndr* 2011; 3: 2.
11. American Diabetes Association. ADA diabetes management guidelines, www.ndei.org/ADA-diabetes-management-guidelines-diagnosis-A1C-testing.aspx.html (2016, accessed 25 April 2017).
12. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus, www.who.int/diabetes/publications/report-hba1c_2011.pdf?ua=1 (2011, accessed 15 April 2018).
13. Wheeler E, Leong A, Liu C-T, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. *PLoS Med* 2017; 14: e1002383.
14. Kim S-Y, Friedmann P, Seth A, et al. Monitoring HIV-infected patients with diabetes: hemoglobin A1c, fructosamine, or glucose? *Clin Med Insights Endocrinol Diabetes* 2014; 7: 41–45.
15. Kim PS, Woods C, Georgoff P, et al. A1C underestimates glycemia in HIV infection. *Diabetes Care* 2009; 32: 11591–11593.
16. Guan X, Zheng L, Sun G, et al. The changing relationship between HbA1c and FBG according to different FBG ranges. *J Endocrinol Invest* 2016; 39: 523–528.
17. Ketema EB and Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. *Arch Public Health* 2015; 73: 43.
18. Ramachandran A, Riddle MC, Kabali C, et al. ORIGIN investigators. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. *Diabetes Care* 2012; 35: 749–753.
19. Slama L, Palella FJ, Abraham AG, et al. Inaccuracy of haemoglobin A1c among HIV-infected men: effects of CD4 cell count, antiretroviral therapies and haematological parameters. *J Antimicrob Chemother* 2014; 69: 3360–3367.
20. Feinstein MJ, Kim J-H, Bibangambah P, et al. Ideal cardiovascular health and carotid atherosclerosis in a mixed cohort of HIV-infected and uninfected Ugandans. *AIDS Res Hum Retroviruses* 2017; 33: 49–56.
21. Siedner MJ, Kim J-H, Nakku RS, et al. HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. *AIDS Lond Engl* 2016; 30: 667–670.
22. ClinicalTrials.gov. Ugandan Non-Communicable Diseases and Aging Cohort (UGANDAC), https://clini

caltrials.gov/ct2/show/NCT02445079 (2017, accessed 16 February 2018).

23. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2018. *Diabetes Care* 2018;41:S13–S27.

24. Bonora E and Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. *Diabetes Care* 2011; 34: S184–S190.

25. Karnchanasorn R, Huang J, Ou H-Y, et al. Comparison of the current diagnostic criterion of HbA1c with fasting and 2-hour plasma glucose concentration. *J Diabetes Res* 2016; 2016: 6195494.

26. Glesby MJ, Hoover DR, Shi Q, et al. Glycated hemoglobin in diabetic women with and without HIV infection: data from the women's interagency HIV study. *Antivir Ther (Lond)* 2010; 15: 571–577.